Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study

The Lancet Oncology

Volumn 15, Issue 13, 2014, Pages 1521-1532

  Lalonde, Emilie ^a,c   Ishkanian, Adrian S ^b   Sykes, Jenna ^e   Fraser, Michael ^c,e   Ross Adams, Helen ^f   Erho, Nicholas ^h   Dunning, Mark J ^f   Halim, Silvia ^f   Lamb, Alastair D ^f,g   Moon, Nathalie C ^a   Zafarana, Gaetano ^c,e   Warren, Anne Y ^g   Meng, Xianyue ^e   Thoms, John ^c,e   Grzadkowski, Michal R ^a   Berlin, Alejandro ^c,e   Have, Cherry L ⁱ   Ramnarine, Varune R ^c,e,j   Yao, Cindy Q ^a,c   Malloff, Chad A ^k   Lam, Lucia L ^h   Xie, Honglei ^a   Harding, Nicholas J ^a   Mak, Denise Y F ^a,l   Chu, Kenneth C ^a,e   Chong, Lauren C ^a   Sendorek, Dorota H ^a   P'ng, Christine ^a   Collins, Colin C ^j   Squire, Jeremy A ^m   Jurisica, Igor ^c,e   Cooper, Colin ^n,o   Eeles, Rosalind ^n,p   Pintilie, Melania ^e   Pra, Alan Dal ^c,e,q   Davicioni, Elai ^h   Lam, Wan L ^h,k   Milosevic, Michael ^c,e   Neal, David E ^f,g   van der Kwast, Theodorus ^c,i   Boutros, Paul C ^a,c,d   Bristow, Robert G ^c,e   more..

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h Center for Drug Research and Development   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^l CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^p INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^q UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HIGH RISK PATIENT; HUMAN; HYPOXIA; IMAGE GUIDED RADIOTHERAPY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; DIAGNOSIS; DNA MICROARRAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; PROGNOSIS; PROSTATE TUMOR; TIME; TUMOR RECURRENCE;

DNA; TUMOR MARKER;

BIOMARKERS, TUMOR; DNA, NEOPLASM; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MICROENVIRONMENT;

EID: 84922592521     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71021-6     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Clin Oncol 2003, 21:2163-2172.
3. Mohler JL The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010, 8:145.
4. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009, 101:1280-1283.
5. Nichol AM, Warde P, Bristow RG Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 2005, 104:891-905.
6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433-439.
7. Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012, 30:1857-1863.
8. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer cell 2010, 18:11-22.
9. Lunt SJ, Chaudary N, Hill RP The tumor microenvironment and metastatic disease. Clin Exp Metastas 2009, 26:19-34.
10. Saylor PJ, Smith MR Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009, 181:1998-2008.
11. Shen MM, Abate-Shen C Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010, 24:1967-2000.
12. Locke JA, Zafarana G, Malloff CA, et al. Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. Prostate 2012, 72:1295-1305.
13. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, 12:245-255.
14. Wu CL, Schroeder BE, Ma XJ, et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci USA 2013, 110:6121-6126.
15. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013, 8:e66855.
16. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011, 17:5878-5888.
17. Dal Pra A, Lalonde E, Sykes J, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 2013, 19:5202-5209.
18. Bristow RG, Hill RP Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
19. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008, 9:342-351.
20. Milosevic M, Warde P, Menard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012, 18:2108-2114.
21. Breiman L Random Forest. Machine Learning 2001, 45:5-32.
22. Roach M, Hanks G, Thames HJ, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
23. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer (accessed June 20, 2014). http://www.uroweb.org/gls/pdf/09%20Prostate%20Cancer_LRLV2.pdf.
24. Liu W, Chang BL, Cramer S, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 2007, 13:5028-5033.
25. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
26. Hieronymus H, Schultz N, Gopalan A, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA 2014, 110:11139-11144.
27. Buffa FM, Harris AL, West CM, Miller CJ Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102:428-435.
28. Winter SC, Buffa FM, Silva P, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67:3441-3449.
29. Eustace A, Mani N, Span PN, et al. A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clin Cancer Res 2013, 19:4879-4888.
30. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012, 4:127rv3.
31. Fritz V, Benfodda Z, Henriquet C, et al. Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth. Oncogene 2013, 32:5101-5110.
32. Yue S, Li J, Lee S-Y, et al. Cholesteryl ester accumulation induced by PTEN Loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 2014, 19:393-406.
33. Young RM, Ackerman D, Quinn ZL, et al. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev 2013, 27:1115-1131.
34. Menon S, Manning BD Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27:S43-S51.
35. Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007, 67:6022-6025.
36. Goodwin JF, Schiewer MJ, Dean JL, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013, 3:1254-1271.